On December 15, 2025, Philips made a public announcement regarding its acquisition of SpectraWAVE, a medical imaging technology firm based in the United States. This strategic move is aimed at solidifying Philips' dominant stance in the realm of image-guided therapy, with a particular focus on coronary intervention and physiological evaluation.

Established in 2017 and with its headquarters situated in Massachusetts, SpectraWAVE boasts a workforce of over 70 individuals. The company has carved out a niche for itself in the field of cutting-edge intravascular imaging technology and AI-powered physiological assessment. Among its key technological offerings are the HyperVue™ imaging system and X1-FFR technology.

The HyperVue™ imaging system ingeniously fuses optical coherence tomography with near-infrared spectroscopy. This combination allows for the generation of AI-aided, high-definition intravascular images of the coronary arteries. On the other hand, the X1-FFR technology facilitates an accurate evaluation of coronary function through a single angiogram procedure.

This acquisition is set to significantly bolster Philips' array of products dedicated to the treatment of coronary artery disease. It will also broaden the range of applications for Philips' image-guided therapy platform, Azurion. Ultimately, this strategic acquisition promises to offer patients across the globe more efficient and safer treatment options.